Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block degradation of cgmp-specific phosphodiesterase type 5 (PDE5) loop GMP in smooth muscle cell lining supplying blood vessels to various tissues.These drugs dilate the cavernous penis, promote erections with sexual stimulation, and are used to treat erectile dysfunction (ED).Sildenafil is the first effective oral therapy for ED.Because PDE5 is also present in the wall of the smooth muscle arterioles of the inner lung, sildenafil and tadalafil dilate these vessels and are FDA approved for the treatment of pulmonary hypertension.
This report contains market size and forecasts of Phosphodiesterase Type 5 (PDE5) Inhibitor in Global, including the following market information:
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Phosphodiesterase Type 5 (PDE5) Inhibitor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Sildenafil Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Phosphodiesterase Type 5 (PDE5) Inhibitor include Eli Lilly, Pfizer, Bayer, Novartis AG, Merck, GlaxoSmithKline plc, Roche, AstraZeneca and BaiYunShan General Factory, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Phosphodiesterase Type 5 (PDE5) Inhibitor companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Segment Percentages, by Type, 2021 (%)
Sildenafil
Tadalafil
Avanafil
Vardenafil
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Segment Percentages, by Application, 2021 (%)
Hospital
Retail Pharmacy
Online Pharmacies
Other
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Phosphodiesterase Type 5 (PDE5) Inhibitor revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Phosphodiesterase Type 5 (PDE5) Inhibitor revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group